Granulocyte transfusions from G-CSF- and dexamethasone-stimulated healthy donors for treatment of patients with severe neutropenia-related infections.
- Author:
Byoung Hwan LEE
1
;
Je Jung LEE
;
Yeo Kyeoung KIM
;
Sang Hee CHO
;
Dong Hyeon SHIN
;
Duck CHO
;
Dong Wook RYANG
;
Moo Rim PARK
;
Ik Joo CHUNG
;
Hyeoung Joon KIM
Author Information
1. Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea. hjoonk@chonnam.ac.kr
- Publication Type:Original Article
- Keywords:
Leukocyte transfusion;
Neutropenia;
Infection;
Granulocyte-colony stimulating factor;
Dexamethasone
- MeSH:
Adrenal Cortex Hormones;
Anti-Infective Agents;
Arrhythmias, Cardiac;
Dexamethasone;
Granulocyte Colony-Stimulating Factor;
Granulocytes*;
Healthy Volunteers;
Humans;
Leukapheresis;
Leukocyte Count;
Leukocyte Transfusion;
Neutropenia;
Neutrophils;
Prospective Studies;
Pulmonary Edema;
Tissue Donors*
- From:Korean Journal of Medicine
2003;64(4):459-467
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Granulocyte transfusions have been used to treat severe, progressive infections in neutropenic patients who fail to respond to antimicrobial agents. Although corticosteroid or granulocyte colony-stimulating factor (G-CSF) were previously used separately to increase leukocyte counts in healthy donors, increasingly G-CSF and corticosteroids are used together, requiring the need to establish the efficacy of this mobilizing regime. METHODS: This prospective study evaluated the safety and efficacy of granulocyte transfusion therapy from donors stimulated with a combination of G-CSF and dexamethasone, in 27 patients with severe neutropenia-related infections. To mobilize granulocytes, healthy volunteer donors received G-CSF, 5 micro gram/kg subcutaneously 12-14 hr before leukapheresis, and dexamethasone, 3 mg/m2 intravenously 15 min before leukapheresis. RESULTS: Donor neutrophil counts were 5,723/micro L (range: 1,500~36,420) at baseline, 22,104/micro L (range: 9,700~41,300) before the injection of dexamethasone, 23,946/micro L (range: 10,900~42,100) immediately before leukapheresis, and 19,913/micro L (range: 9,100~36,300) after leukapheresis. Ninety-two leukapheresis procedures were performed with a mean yield of 7.88 10(10) granulocytes (range: 2.2~17.9 10(10)). The mobilizing agents were well tolerated in the donors. Of the patients, 16 (59.3%) showed favorable responses, whereas 11 (40.7%) had unfavorable responses. Adverse reactions to the therapy were arrhythmia in two patients (7.4%) and pulmonary edema in one patient (3.7%). Favorable responses were seen in 83.3, 76.9, and 45.5% of the patients from whom fungal, Gram-negative, and Gram-positive organisms were isolated, respectively. CONCLUSION: This study suggests that the combination of G-CSF and dexamethasone is an effective, well-tolerated regimen for mobilizing granulocytes from healthy donors, and that granulocyte transfusion therapy is useful for neutropenic patients, especially those with fungal or Gram-negative infections that are resistant to appropriate antimicrobial agents.
